GlassScriptPhysician profile
John Brabant
NPI 1629448527
$25,844.75
in general payments reported to CMS, 2019-2025
27 companies · $749 in 2025
The $749 reported for 2025 was more than what 75% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $47.18 · 2022: $17K · 2023: $7,766 · 2024: $299 · 2025: $749.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,139 · Food and Beverage: $2,424 · Travel and Lodging: $1,250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,139.00 |
| Food and Beverage | $2,424.40 |
| Travel and Lodging | $1,250.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $13,827.01 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $10,365.29 | 2022-2025 | |
| Lilly USA, LLC | $286.23 | 2022-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $152.58 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $141.13 | 2023-2025 | Rexulti |
| Exact Sciences Corporation | $123.26 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $96.02 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $88.93 | 2022-2023 | Trintellix |
| Merck Sharp & Dohme LLC | $87.63 | 2023-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Glaxosmithkline, LLC. | $76.07 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $75.75 | 2025 | |
| Amgen INC. | $72.21 | 2023-2025 | Repatha, Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $64.81 | 2022-2023 | |
| Astellas Pharma US INC | $62.26 | 2021-2023 | Veozah |
| Corium, LLC | $61.52 | 2022-2023 | Adlarity |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $53.16 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Phathom Pharmaceuticals, INC. | $39.23 | 2024-2025 | Voquezna |
| Amarin Pharma, INC. | $23.19 | 2022 | |
| Mayne Pharma Commercial LLC | $20.87 | 2023 | |
| Lundbeck LLC | $20.57 | 2023 | Rexulti |
| Alexion Pharmaceuticals, INC. | $19.79 | 2023 | Strensiq |
| Avanir Pharmaceuticals, INC. | $16.73 | 2022 | |
| Dynavax Technologies Corporation | $15.30 | 2022 | |
| Esperion Therapeutics, INC. | $14.05 | 2025 | Nexletol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.04 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $13.97 | 2024 | Zoryve |
| Medtronic, INC. | $13.15 | 2023 | Endurant Iis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Brabant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.